-
ÐÇ¿ÕÊÓƵ Website
-
Improving the UK's health data capability & the industry's access to data
- ÐÇ¿ÕÊÓƵ Health Data Use Case Study Library
ÐÇ¿ÕÊÓƵ Health Data Use Case Study Library
Introduction
To help understand why ÐÇ¿ÕÊÓƵ data is crucial for research, developing innovative, safe, and effective medicines, we have created a publicly accessible case study library.
This new ÐÇ¿ÕÊÓƵ health data case study library contains examples of how the pharmaceutical industry has used ÐÇ¿ÕÊÓƵ data in medical research and the benefits that have emerged as a result. These examples cover different therapeutic areas, datasets and types of research.
Why the pharmaceutical industry needs ÐÇ¿ÕÊÓƵ data to develop new medicinesÂ
To accompany the launch of the Industry Use of Health Data Case Study Library, ÐÇ¿ÕÊÓƵ Executive Director for Research and Innovation, Janet Valentine, explains why it is important for the pharmaceutical industry to access to anonymised ÐÇ¿ÕÊÓƵ data for research to develop new safe and effective medicines that benefit patients in the UK and globally.
Global patterns in hip fractures: trends in occurrence, treatment, and survival - Amgen
Hip fractures relating to weak and brittle bones are a global public health concern, with over 10 million cases per year globally.
Do type 2 diabetes medicine trial results reflect the UK patient population? - Eli Lilly
Cardiovascular disease (CVD) is a leading cause of death and illness among individuals with type 2 diabetes (T2D).
Understanding the safety of the drug eliglustat over time for adults with Gaucher disease - Sanofi
Gaucher disease is a rare genetic condition where fatty substances build up in organs, like the liver, spleen and bones.
A thorough investigation of patient genetic data to improve treatments for specific conditions - UCB
Many causes of disease are associated with an individual’s genetic make-up and there is increasing interest in medical research to understand how our genes might influence our chances of getting a disease.